10-year analysis of human immunodeficiency virus incidence in first-time and repeat donors in Brazil

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMATEOS, Sheila de Oliveira Garcia
dc.contributor.authorPREISS, Liliana
dc.contributor.authorGONCALEZ, Thelma T.
dc.contributor.authorOLIVEIRA, Claudia Di Lorenzo
dc.contributor.authorGREBE, Eduard
dc.contributor.authorGERMANIO, Clara Di
dc.contributor.authorSTONE, Mars
dc.contributor.authorAMORIM FILHO, Luiz
dc.contributor.authorPROIETTI, Anna Barbara Carneiro
dc.contributor.authorBELISARIO, Andre Rolim
dc.contributor.authorALMEIDA-NETO, Cesar de
dc.contributor.authorMENDRONE-JUNIOR, Alfredo
dc.contributor.authorLOUREIRO, Paula
dc.contributor.authorBUSCH, Michael P.
dc.contributor.authorCUSTER, Brian
dc.contributor.authorSABINO, Ester Cerdeira
dc.contributor.groupauthorRecipient Epidemiology Donor Eva
dc.date.accessioned2021-04-15T19:53:29Z
dc.date.available2021-04-15T19:53:29Z
dc.date.issued2021
dc.description.abstractBackground and objectives Incidence in first-time and repeat blood donors is an important measure of transfusion-transmitted HIV infection (TT-HIV) risk. This study assessed HIV incidence over time at four large blood centres in Brazil. Materials and methods Donations were screened and confirmed using serological assays for HIV from 2007 to 2016, and additionally screened by nucleic acid testing from 2011 forward. Limiting antigen (LAg) avidity testing was conducted on HIV seroreactive samples from first-time donors to classify whether an infection was recently acquired. We calculated incidence in first-time donors using the mean duration of recent infection and in repeat donors using classical methods. Time and demographic trends were assessed using Poisson regression. Results Over the 10-year period, HIV incidence in first-time donors was highest in Recife (45 center dot 1/100 000 person-years (10(5)py)) followed by Sao Paulo (32 center dot 2/10(5)py) and then Belo Horizonte (23 center dot 3/10(5)py), and in repeat donors was highest in Recife (33 center dot 2/10(5)py), Belo Horizonte (27 center dot 5/10(5)py) and Sao Paulo (17 center dot 0/10(5)py). Results from Rio de Janeiro were available from 2013 to 2016 with incidence in first-time donors of 35 center dot 9/10(5)py and repeat donors from 2011 to 2016 of 29 center dot 2/10(5)py. Incidence varied by other donor demographics. When incidence was considered in 2-year intervals, no significant trend was evident. Overall residual risk of TT-HIV was 5 center dot 46 and 7 center dot 41 per million units of pRBC and FFP transfused, respectively. Conclusion HIV incidence in both first-time and repeat donors varied by region in Brazil. Clear secular trends were not evident.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipU.S. National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) Recipient Epidemiology and Donor Evaluation Study (REDS-III), International Component Brazil [HHSN268201100007I]
dc.description.sponsorshipVRI
dc.description.sponsorshipUCSF from NIH: National Institute of Mental Health (NIMH), Center for AIDS Prevention Studies [P30 MH062246]
dc.description.sponsorshipInternational Traineeships in AIDS Prevention Studies (ITAPS) [R25MH064712]
dc.identifier.citationVOX SANGUINIS, v.116, n.2, p.207-216, 2021
dc.identifier.doi10.1111/vox.13002
dc.identifier.eissn1423-0410
dc.identifier.issn0042-9007
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/39882
dc.language.isoeng
dc.publisherWILEYeng
dc.relation.ispartofVox Sanguinis
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright WILEYeng
dc.subjectblood safetyeng
dc.subjectdonorseng
dc.subjectresidual risk estimationeng
dc.subjectserological testingeng
dc.subjecttransfusion- transmissible infectionseng
dc.subject.otherhepatitis-c viruseng
dc.subject.otherresidual riskeng
dc.subject.otherblood-donorseng
dc.subject.otherviral transmissioneng
dc.subject.othertest-seekingeng
dc.subject.otherhiveng
dc.subject.othertransfusioneng
dc.subject.otherprevalenceeng
dc.subject.otherseroconversioneng
dc.subject.otherinfectionseng
dc.subject.wosHematologyeng
dc.title10-year analysis of human immunodeficiency virus incidence in first-time and repeat donors in Brazileng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.author.externalPREISS, Liliana:RTI Int, Div Biostat & Epidemiol, Rockville, MD USA
hcfmusp.author.externalGONCALEZ, Thelma T.:Vitalant Res Inst, San Francisco, CA USA
hcfmusp.author.externalOLIVEIRA, Claudia Di Lorenzo:Univ Fed Sao Joao del Rei, Sao Joao Del Rei, MG, Brazil
hcfmusp.author.externalGREBE, Eduard:Vitalant Res Inst, San Francisco, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA
hcfmusp.author.externalGERMANIO, Clara Di:Vitalant Res Inst, San Francisco, CA USA
hcfmusp.author.externalSTONE, Mars:Vitalant Res Inst, San Francisco, CA USA
hcfmusp.author.externalAMORIM FILHO, Luiz:Hemorio, Dept Hemotherapy, Rio De Janeiro, Brazil
hcfmusp.author.externalPROIETTI, Anna Barbara Carneiro:Hemominas, Dept GDTC Tech Sci Dev Management, Belo Horizonte, MG, Brazil
hcfmusp.author.externalBELISARIO, Andre Rolim:Hemominas, Dept GDTC Tech Sci Dev Management, Belo Horizonte, MG, Brazil
hcfmusp.author.externalLOUREIRO, Paula:Univ Pernambuco, Recife, PE, Brazil; Fundacao Hemope, Hemoctr Pernambuco, Recife, PE, Brazil
hcfmusp.author.externalBUSCH, Michael P.:Vitalant Res Inst, San Francisco, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA
hcfmusp.author.externalCUSTER, Brian:Vitalant Res Inst, San Francisco, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA
hcfmusp.citation.scopus6
hcfmusp.contributor.author-fmusphcSHEILA DE OLIVEIRA GARCIA MATEOS
hcfmusp.contributor.author-fmusphcCESAR DE ALMEIDA NETO
hcfmusp.contributor.author-fmusphcALFREDO MENDRONE JUNIOR
hcfmusp.contributor.author-fmusphcESTER CERDEIRA SABINO
hcfmusp.description.beginpage207
hcfmusp.description.endpage216
hcfmusp.description.issue2
hcfmusp.description.volume116
hcfmusp.origemWOS
hcfmusp.origem.pubmed32996602
hcfmusp.origem.scopus2-s2.0-85095988621
hcfmusp.origem.wosWOS:000573614100001
hcfmusp.publisher.cityHOBOKENeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referencean der Heiden M, 2015, VOX SANG, V108, P123, DOI 10.1111/vox.12204eng
hcfmusp.relation.referenceANVISA: Agencia Nacional de Vigilancia Sanitaria, 2018, ANVISA PROD HEMOTERAeng
hcfmusp.relation.referenceBrambilla DJ, 2017, TRANSFUSION, V57, P823, DOI 10.1111/trf.13939eng
hcfmusp.relation.referenceBruhn R, 2013, TRANSFUSION, V53, P2399, DOI 10.1111/trf.12299eng
hcfmusp.relation.referenceBusch MP, 1996, TRANSFUS CLIN BIOL, V3, P7, DOI 10.1016/S1246-7820(96)80007-3eng
hcfmusp.relation.referenceCarneiro-Proietti ABF, 2012, AIDS RES HUM RETROV, V28, P1265, DOI 10.1089/aid.2011.0143eng
hcfmusp.relation.referenceCorporation SB, 2018, SED HIV 1 LAG AV EIA, V1, P1eng
hcfmusp.relation.referenceNeto CD, 2012, TRANSFUSION, V52, P722, DOI 10.1111/j.1537-2995.2011.03358.xeng
hcfmusp.relation.referenceDuong YT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114947eng
hcfmusp.relation.referenceFiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005eng
hcfmusp.relation.referenceKeating SM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222290eng
hcfmusp.relation.referenceMa ZM, 2009, J VIROL, V83, P3288, DOI 10.1128/JVI.02423-08eng
hcfmusp.relation.referenceMoreno EC, 2019, HEMATOL TRANSF CELL, V41, P229, DOI 10.1016/j.htct.2018.11.002eng
hcfmusp.relation.referenceVieira PCM, 2017, TRANSFUSION, V57, P1968, DOI 10.1111/trf.14146eng
hcfmusp.relation.referenceO'Brien SF, 2017, TRANSFUS APHER SCI, V56, P389, DOI 10.1016/j.transci.2017.03.010eng
hcfmusp.relation.referenceOliveira CDL, 2013, VOX SANG, V104, P100, DOI 10.1111/j.1423-0410.2012.01643.xeng
hcfmusp.relation.referencePillonel J, 2005, Euro Surveill, V10, P5eng
hcfmusp.relation.referenceRocha D, 2018, TRANSFUSION, V58, P862, DOI 10.1111/trf.14478eng
hcfmusp.relation.referenceSabino EC, 2012, TRANSFUSION, V52, P870, DOI 10.1111/j.1537-2995.2011.03344.xeng
hcfmusp.relation.referenceSchlenke P, 2014, TRANSFUS MED HEMOTH, V41, P309, DOI 10.1159/000365646eng
hcfmusp.relation.referenceTruong HHM, 2015, AIDS BEHAV, V19, P1574, DOI 10.1007/s10461-015-1036-8eng
hcfmusp.relation.referenceVelati C, 2018, BLOOD TRANSFUS-ITALY, V16, P422, DOI 10.2450/2018.0069-18eng
hcfmusp.relation.referenceVermeulen M, 2019, TRANSFUSION, V59, P267, DOI 10.1111/trf.14959eng
hcfmusp.relation.referenceWeusten J, 2011, TRANSFUSION, V51, P203, DOI 10.1111/j.1537-2995.2010.02804.xeng
hcfmusp.relation.referenceWorld Health Organization, 2019, BLOOD SAF AVeng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationf95268f1-10bc-45ac-9699-a60b29213bb2
relation.isAuthorOfPublication97cdde77-5f90-4f99-a5eb-9275a5d55e78
relation.isAuthorOfPublication4a7139e3-a8d0-4218-8aeb-fdd2698cbdd0
relation.isAuthorOfPublication7d122e95-afc6-426e-9255-72fdf621b547
relation.isAuthorOfPublication.latestForDiscoveryf95268f1-10bc-45ac-9699-a60b29213bb2
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_MATEOS_10year_analysis_of_human_immunodeficiency_virus_incidence_in_2021.PDF
Tamanho:
199.2 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - LIM/46
Artigos e Materiais de Revistas Científicas - ODS/03